BioAge discontinues mid-stage trial of obesity drug (updated)

BioAge Labs

06/12/2024 21:53

(Adds details in paragraphs 2-4)
       Dec 6 (Reuters) - BioAge Labs  BIOA.O  said on Friday it
is discontinuing its mid-stage trial studying its experimental
drug as a monotherapy and in combination with Eli Lilly's
 LLY.N  tirzepatide for the treatment of obesity.
    The drug developer decided to stop the trial after liver
transaminitis, or high levels of certain liver enzymes, were
observed in patients receiving the experimental drug, azelaprag.
        Tirzepatide is the active ingredient in Lilly's diabetes
drug Mounjaro and weight-loss treatment Zepbound. 
  
        The mid-stage trial enrolled about 220 individuals with
obesity aged 55 years and older.
  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shreya
Biswas)
 ((Sriparna.Roy@thomsonreuters.com;))